Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP).
In: Vaccine Weekly, 2024-06-21, S. 95-95
serialPeriodical
Zugriff:
This document provides information about a clinical trial, NCT06441747, that is investigating the potential benefits of combining durvalumab and olaparib in the maintenance treatment of patients with locally advanced or metastatic cholangiocarcinoma, a type of liver cancer. The trial aims to evaluate the efficacy, toxicity, progression-free survival, and overall survival of this combination therapy. It outlines the eligibility criteria for participants and provides administrative information about the trial, such as contact details and collaborators. The study is currently in the recruitment phase and is expected to start in August 2024, with an estimated completion date of August 2028. [Extracted from the article]
Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP).
|
---|---|
Zeitschrift: | Vaccine Weekly, 2024-06-21, S. 95-95 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1074-2921 (print) |
Schlagwort: |
|
Sonstiges: |
|